Table 2.

Primary and secondary efficacy clinical events in patients with and without diabetes mellitus

Endpoint	Diabetes				Non-diabetes				Interaction P value*
	Evacetrapib n/N (KM estimate)	Placebo n/N (KM estimate)	HR (95% CI)	P value	Evacetrapib n/N (KM estimate)	Placebo n/N (KM estimate)	HR (95% CI)	P value
Primary composite†	564/4127 (14.5)	589/4109 (16.0)	0.95 (0.85 to 1.07)	0.38	201/1911 (11.5)	175/1945 (9.7)	1.17 (0.96 to 1.44)	0.12	0.075
Cardiovascular death	116/4127 (3.1)	134/4109 (3.7)	0.86 (0.67 to 1.10)	0.23	20/1911 (1.2)	26/1945 (1.5)	0.78 (0.43 to 1.39)	0.40	0.76
Myocardial infarction	189/4126 (4.9)	186/4108 (4.9)	1.01 (0.83 to 1.24)	0.92	62/1910 (3.7)	69/1944 (3.8)	0.91 (0.65 to 1.29)	0.60	0.61
Stroke	64/4127 (1.7)	77/4109 (2.2)	0.83 (0.59 to 1.15)	0.25	27/1911 (1.6)	19/1945 (1.0)	1.45 (0.80 to 2.60)	0.22	0.10
Hospitalization for unstable angina	113/4127 (3.0)	106/4109 (2.9)	1.06 (0.81 to 1.38)	0.67	40/1911 (2.2)	37/1945 (2.1)	1.10 (0.70 to 1.72)	0.68	0.90
Coronary revascularization	351/4127 (9.2)	360/4109 (9.9)	0.97 (0.84 to 1.12)	0.67	132/1911 (7.4)	118/1945 (6.5)	1.14 (0.89 to 1.46)	0.31	0.28
Triple composite‡	319/4127 (8.2)	346/4109 (9.4)	0.91 (0.79 to 1.06)	0.25	105/1911 (6.3)	98/1945 (5.5)	1.09 (0.83 to 1.44)	0.54	0.27
All-cause mortality	176/4127 (4.6)	206/4109 (5.7)	0.85 (0.69 to 1.04)	0.11	43/1911 (2.6)	58/1945 (3.4)	0.75 (0.51 to 1.11)	0.15	0.58

*For interaction between status of diabetes and treatment assigned.

†The primary composite endpoint was the time to first occurrence of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization.

‡The triple composite endpoint was the time to first occurrence of cardiovascular death, myocardial infarction or stroke.

KM, Kaplan-Meier.